Bilaketaren emaitzak - Lynette Chee

  • Erakusten 1 - 12 emaitzak -- 12
Findu emaitzak
  1. 1
    Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation

    Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation nork Ashvind Prabahran, Rachel Koldej, Lynette Chee, David Ritchie

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021

    Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021 nork Anna Khanina, Shio Yen Tio, Michelle Ananda‐Rajah, Sarah Kidd, Eloise Williams, Lynette Chee, Karen Urbancic, Karin Thursky

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy

    Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy nork Narendranath Epperla, Ang Li, Brent R. Logan, Caitrin Fretham, Saurabh Chhabra, Mahmoud Aljurf, Lynette Chee, Edward A. Copelan, César O. Freytes, Peiman Hematti, Hillard M. Lazarus, Mark R. Litzow, Taiga Nishihori, Richard F. Olsson, Tim Prestidge, Wael Saber, Baldeep Wirk, Jean A. Yared, Alison W. Loren, Marcelo C. Pasquini

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE

    S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE... nork Delphine Réa, Andreas Hochhaus, Michael J. Mauro, Yasunori Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, D.-W. Kim, Jane F. Apperley, Jorge E. Cortés, André Abdo, Laura Fogliatto, D. D. H Kim, Philipp le Coutre, S. Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, Koji Sasaki, S. S. Kapoor, Alejandro Allepuz, Sara Quenet, Véronique Bédoucha, Carla Boquimpani

    Argitaratua 2022
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

    Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic M... nork Michael J. Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, Jorge E. Cortés, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, Koji Sasaki, C. FREITAS, S. S. Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Réa

    Argitaratua 2023
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

    Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL nork Michael J. Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, Jorge E. Cortés, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, Koji Sasaki, Carla Boquimpani, S. S. Kapoor, Noemi Espurz-Abad, Vishal Dhamal, Delphine Réa

    Argitaratua 2025
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

    Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic... nork Andreas Hochhaus, Carla Boquimpani, Delphine Réa, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, Jorge E. Cortés, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D. le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, Koji Sasaki, Paola Aimone, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs nork Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentín García‐Gutiérrez, Jorge E. Cortés, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus

    Argitaratua 2021
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

    Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leu... nork Michael J. Mauro, Yosuke Minami, Delphine Réa, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, Jorge E. Cortés, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D. le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, Koji Sasaki, S. S. Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani

    Argitaratua 2021
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL nork Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E. Cortés, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, André Abdo, Laura Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saußele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, S. S. Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J. Mauro

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT

    Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT nork Rohtesh S. Mehta, Shernan G. Holtan, Tao Wang, Michael Hemmer, Stephen R. Spellman, Mukta Arora, Daniel R. Couriel, Amin M. Alousi, Joseph Pidala, Hisham Abdel‐Azim, Vaibhav Agrawal, Ibrahim Ahmed, A. Samer Al‐Homsi, Mahmoud Aljurf, Joseph H. Antin, Medhat Askar, Jeffery J. Auletta, Vijaya Raj Bhatt, Lynette Chee, Saurabh Chhabra, Andrew Daly, Zachariah DeFilipp, James Gajewski, Robert Peter Gale, Usama Gergis, Peiman Hematti, Gerhard Hildebrandt, William J. Hogan, Yoshihiro Inamoto, Rodrigo Martino, Navneet S. Majhail, David I. Marks, Taiga Nishihori, Richard F. Olsson, Attaphol Pawarode, Miguel Ángel Díaz, Tim Prestidge, Hemalatha G. Rangarajan, Olle Ringdén, Ayman Saad, Bipin N. Savani, Hélène Schoemans, Sachiko Seo, Kirk R. Schultz, Melhem Solh, Thomas R. Spitzer, Jan Storek, Takanori Teshima, Leo F. Verdonck, Baldeep Wirk, Jean A. Yared, Jean‐Yves Cahn, Daniel J. Weisdorf

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells

    Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells nork Thi H. O. Nguyen, Louise C. Rowntree, Lilith F. Allen, Brendon Y. Chua, Łukasz Kedzierski, Chhay Lim, Masa Lasica, Gayani S Tennakoon, Natalie R Saunders, Megan Crane, Lynette Chee, John F. Seymour, Mary Ann Anderson, Ashley Whitechurch, E. Bridie Clemens, Wuji Zhang, So Young Chang, Jennifer R. Habel, Xiaoxiao Jia, Hayley A. McQuilten, Anastasia A. Minervina, Mikhail V. Pogorelyy, Priyanka Chaurasia, Jan Petersen, Tejas Menon, Luca Hensen, Jessica A. Neil, Francesca L. Mordant, Hyon‐Xhi Tan, Aira F. Cabug, Adam K. Wheatley, Stephen J. Kent, Kanta Subbarao, Theo Karapanagiotidis, Han Huang, Lynn K. Vo, Natalie Cain, Suellen Nicholson, Florian Krammer, Grace Gibney, Fiona James, Janine M. Trevillyan, Jason A. Trubiano, Jeni Mitchell, Britt Christensen, Katherine Bond, Deborah A. Williamson, Jamie Rossjohn, Jeremy Chase Crawford, Paul G. Thomas, Karin Thursky, Monica A. Slavin, Constantine S. Tam, Benjamin W. Teh, Katherine Kedzierska

    Argitaratua 2023
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: